Therapeutic Protein/Peptide Drugs
  • Extemely short half life
  • Low bioavalability
  • Immunogenicity/antigenicity
  • Rapid proteolysis by enzyme
    		•
    PEG-Protein/Peptide Drugs
  • Extended circulating half-life
  • Lower toxicity
       (immunogenicity/antigenicity)
  • Increased drug stability
  • Enhanced drug solubility




    •